Chi-Med, Eli Lil­ly score a land­mark ap­proval in Chi­na for the first new can­cer drug de­vel­oped in Chi­na

Hutchi­son Chi­na MediTech CEO Chris­t­ian Hogg just nabbed im­por­tant brag­ging rights to the first full ap­proval of a ma­jor can­cer drug that was made in Chi­na and now will be sold in Chi­na.

Al­lied with Eli Lil­ly, Chi-Med says that fruquin­tinib will be mar­ket­ed as Elu­nate for col­orec­tal can­cer.

“Elu­nate is the first home-grown, Chi­na-dis­cov­ered and de­vel­oped drug we are aware of in an on­col­o­gy in­di­ca­tion to be un­con­di­tion­al­ly ap­proved through a ran­dom­ized clin­i­cal tri­al in Chi­na,” said chair­man Si­mon To. “This is the re­sult of over a dozen years of stead­fast com­mit­ment by Chi-Med in re­search and de­vel­op­ment in Chi­na’s emerg­ing biotech ecosys­tem.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER